Why You Should Measure Comparability Debt Before Ever Starting A Study

This recent article by Siddharth Krishnan, Director and Principal Consultant at Cellvanta Ltd in Cell&Gene discusses the recurring challenge of demonstrating process and analytical comparability in cell and gene therapy development. 

Comparability is often treated as a problem that begins when a manufacturing or analytical change occurs. The article introduces “comparability debt” to describe the technical uncertainty that can accumulate earlier, when product and process understanding and analytical capability develop at different rates. 

Read the full article here